- Baker Brothers’ 13F portfolio value decreased from $15.18B to $12.21B.
- Amarin Corp plc (AMRN) and Acadia Pharma stakes were increased during the quarter.
- The top-three positions are Seattle Genetics (SGEN), Incyte Corporation (INCY), and BeiGene (BGNE) and they add up to almost ~55% of the portfolio.
This article is part of a series that provides an ongoing
analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly
basis. It is based on Baker Brothers’ regulatory 13F Form filed on 02/14/2019.
This quarter, Baker Brothers’ 13F portfolio value decreased
~20% from $15.18B to $12.21B. The top three holdings are at ~55% while the top
five holdings are close to ~68% of the 13F assets: Seattle Genetics (SGEN),
Incyte Corporation (INCY), BeiGene (BGNE), Alexion Pharmaceuticals (ALXN), and
Genomic Health (GHDX).
The spreadsheet below highlights changes to Baker Brothers’
13F holdings in Q4 2018. For a look at how the portfolio has progressed, please
see our previous
update:
To learn more about how to profit from a strategy of
following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little
Guy .
No comments :
Post a Comment